ANNOUNCEMENT

Join us at MedCity CONVERGE July 9-10 in Philadelphia, and hear from ALL healthcare innovation sectors.

Topic: Athersys

Stem cell company Athersys expects more R&D spending, potential partnerships in 2013

Stem cell company Athersys expects more R&D spending, potential partnerships in 2013

March 13, 2013 10:16 am by | 1 Comments

Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can ... Read more
Why is Athersys suddenly hyping its preclinical obesity drug?

Why is Athersys suddenly hyping its preclinical obesity drug?

May 23, 2012 9:19 am by | 0 Comments

It isn’t easy to get profit-hungry Wall Street excited about a drug that hasn’t yet been tested in humans and is at best years and years away from generating any ... Read more
Athersys-Pfizer IBD phase 2 trial to wrap up by end of the year

Athersys-Pfizer IBD phase 2 trial to wrap up by end of the year

May 14, 2012 5:42 pm by | 0 Comments

Stem cell therapeutics developer Athersys’ (NASDAQ:ATHX) phase 2 clinical study investigating the treatment of inflammatory bowel disease with partner Pfizer (NYSE:PFE) is expected to complete patient enrollment by the end ... Read more
Athersys touts stem cell technology as treatment for rare Hurler’s syndrome

Athersys touts stem cell technology as treatment for rare Hurler’s syndrome

April 20, 2012 10:02 am by | 0 Comments

Results of a preclinical study suggest that stem cell technology from Athersys (NASDAQ:ATHX) could offer a treatment for patients suffering from a rare disorder called “Hurler’s syndrome.”Hurler’s syndrome is a ... Read more
Athersys awarded stem cell patent for graft-versus-host disease

Athersys awarded stem cell patent for graft-versus-host disease

April 4, 2012 9:28 am by | 0 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembryonic, multipotent stem cells in the treatment of graft-versus-host disease.Graft-versus-host disease (GvHD) often occurs after ... Read more
Athersys CEO: Stroke therapy could be one of biggest blockbusters ever

Athersys CEO: Stroke therapy could be one of biggest blockbusters ever

April 2, 2012 10:36 am by | 2 Comments

Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in cautious and measured tones, but he made a brash statement in the company’s most ... Read more
Athersys gets OK for German solid organ transplant clinical trial

Athersys gets OK for German solid organ transplant clinical trial

March 27, 2012 5:40 pm by | 0 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has received German regulatory clearance for a physician-sponsored solid organ transplant clinical trial.The study will enroll up to 24 patients and examine Athersys’ MultiStem technology ... Read more
Stem cell company Athersys secures $9M in private stock sale

Stem cell company Athersys secures $9M in private stock sale

March 9, 2012 11:38 am by | 0 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor.Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and ... Read more
Athersys, University Hospitals partner for clinical trials of MultiStem for stroke

Athersys, University Hospitals partner for clinical trials of MultiStem for stroke

February 22, 2012 2:12 pm by | 0 Comments

University Hospitals Case Medical Center will be one of 25 institutions in the U.S. to take part in a phase 2 clinical trial of a stem cell treatment for stroke ... Read more
Athersys touts results of phase 1 blood diseases trial

Athersys touts results of phase 1 blood diseases trial

February 1, 2012 3:38 pm by | 0 Comments

Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases.The trial showed that the company’s MultiStem technology ... Read more
Stem cell company Athersys gets grant to study traumatic brain injury

Stem cell company Athersys gets grant to study traumatic brain injury

February 1, 2012 11:00 am by | 0 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain ... Read more
Athersys gets U.S. stem cell patent for heart attack, other conditions

Athersys gets U.S. stem cell patent for heart attack, other conditions

January 4, 2012 9:17 am by | 0 Comments

Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent stem cells for the treatment of several heart conditions, including heart attack.The patent provides protection for ... Read more
Athersys closes $20 million stock purchase deal with Aspire Capital

Athersys closes $20 million stock purchase deal with Aspire Capital

November 14, 2011 3:28 pm by | 0 Comments

A new common stock purchase agreement with Aspire Capital Fund LLC will give Cleveland biopharmaceutical company Athersys (NASDAQ:ATHX) up to $20 million in investment dollars.Chicago-based Aspire has committed to purchasing ... Read more
Athersys to investigate stem cell treatment for multiple sclerosis

Athersys to investigate stem cell treatment for multiple sclerosis

October 21, 2011 8:16 am by | 0 Comments

Athersys (Nasdaq:ATHX) has entered a partnership with a nonprofit multiple sclerosis group to investigate its adult stem cell technology for the treatment of MS.Fast Forward, a nonprofit subsidiary of the ... Read more
Athersys reveals plans for phase 2 stroke clinical trial

Athersys reveals plans for phase 2 stroke clinical trial

September 28, 2011 9:12 am by | 1 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has taken the next of many steps toward commercializing its MultiStem therapy for stroke, the most promising application for the therapy.The Cleveland-based company detailed its ... Read more